Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved a label expansion of Reblozyl (luspatercept).The EC expanded the drug’s label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (EU) member states.The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior eff ...